Glomerulonephritis
MONDO:0002462A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.
Also known as: glomerular nephritis, glomerulonephritis, glomerulonephritis (disease), nephritis of renal glomerulus, renal glomerulus nephritis, bright's disease
458 clinical trials for this condition and its sub-types, 33 tagged with Glomerulonephritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Glomerulonephritis
-
Lupus nephritis 140 trials
-
IgA glomerulonephritis 123 trials
-
Granulomatosis with polyangiitis 95 trials · 115 incl. sub-types
1 sub-type
-
Membranous glomerulonephritis 70 trials · 78 incl. sub-types
1 sub-type
- Idiopathic membranous glomerulonephritis 51 trials
-
Lipoid nephrosis 32 trials
-
Primary membranoproliferative glomerulonephritis 0 trials · 26 incl. sub-types
3 sub-types
- Complement 3 glomerulopathy 23 trials · 24 incl. sub-types Sub-types →
- Immunoglobulin-mediated membranoproliferative glomerulonephritis 12 trials
- Membranoproliferative glomerulonephritis, X-linked 0 trials
-
Membranoproliferative glomerulonephritis 11 trials
-
Pauci-immune glomerulonephritis 1 trial · 5 incl. sub-types
2 sub-types
-
Rapidly progressive glomerulonephritis 3 trials · 4 incl. sub-types
1 sub-type
-
Proliferative glomerulonephritis 1 trial · 2 incl. sub-types
1 sub-type
- Acute proliferative glomerulonephritis 0 trials · 1 incl. sub-types Sub-types →
-
Immunotactoid glomerulopathy 1 trial
-
Autoimmune glomerulonephritis 0 trials
-
Diffuse glomerulonephritis 0 trials
1 sub-type
- Acute diffuse glomerulonephritis 0 trials
-
Exudative glomerulonephritis 0 trials
-
Focal embolic glomerulonephritis 0 trials
-
Immune-complex glomerulonephritis 0 trials
-
Subacute glomerulonephritis 0 trials
Most studied deeper sub-types
-
New drug combo shows promise for kidney disease in small trial
Disease control CompletedThis study tested whether adding the drug atrasentan to standard care (including SGLT2 inhibitors) can reduce protein in the urine of people with IgA nephropathy, a kidney disease. 54 adults with biopsy-confirmed IgA nephropathy participated. The main goal was to see if atrasenta…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug shows promise for kidney disease in early trial
Disease control CompletedThis early-stage study tested a drug called mezagitamab in 17 people with IgA nephropathy, a kidney disease. The main goal was to check for side effects and see how the body processes the drug. Participants received injections under the skin for several weeks and were monitored f…
Phase 1 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug shows promise for slowing kidney disease in Non-Diabetic patients
Disease control CompletedThis study tested whether finerenone, a drug that blocks a hormone involved in kidney damage, can reduce protein in urine and slow kidney function decline. One hundred adults with non-diabetic glomerulonephritis took either finerenone or a placebo for 9 months, on top of their us…
Phase 2 • Sponsor: Alexandria University • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug shows promise for kidney disease in phase 2 trial
Disease control CompletedThis study tested a new drug called VIS649 in 155 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo, and researchers monitored sid…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could efgartigimod tame lupus nephritis? early trial hints at hope
Disease control CompletedThis phase 2 study tested the drug efgartigimod in 73 Chinese patients with active lupus nephritis, a serious kidney complication of lupus. Participants received either the drug or a placebo by IV infusion over 24 weeks. The main goal was to see if the drug could reduce protein i…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Steroids for kidney disease: do they prevent failure Long-Term?
Knowledge-focused CompletedThis study follows 211 people with IgA nephropathy who previously took a 6-9 month course of the steroid methylprednisolone in the TESTING trial. Researchers want to see if the steroid helped prevent end-stage kidney disease (needing dialysis or a transplant) over the long term. …
Sponsor: The George Institute • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Worldwide kidney study tracks 6,000 patients to unlock disease secrets
Knowledge-focused CompletedThis study followed nearly 6,000 people with kidney disease from around the world. Researchers collected routine test results like kidney function and protein in urine to better understand how the disease progresses. The goal was to gather information, not to test a new treatment…
Sponsor: The George Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC